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Abstract. The aim of this study was to investigate the expres-
sion of bone morphogenetic protein 7 (BMP7), in human 
pulmonary cancer tissues/cells and to evaluate the cellular 
impact of bone morphogenetic proteins on pulmonary cancer 
cells. BMP7 expression was determined in human lung cancer 
cell lines. The invasiveness and growth of cells transfected 
with BMP7, in vitro, were evaluated using the in vitro inva-
sion assay and in vitro tumour models. Cellular migration 
was analysed using wounding assays. BMP7-positive tumours 
correlated with the absence of bone metastasis (P=0.040). In 
this analysis, we identified that 4 of 4 small cell lung cancer 
(SCLC) tissue specimens had no BMP7 expression, which 
illustrated that BMP7 may have no role in SCLC. BMP7 
expression was not correlated with the overall survival time 
in lung cancer patients. Downregulation of BMP7 expres-
sion significantly inhibited the invasiveness of SPC-A1 cells 
(P<0.001) and forced-expression of BMP7 dramatically 
increased the motility of A549 cells. Overexpression of BMP7 
in A549 cells and its knockdown in SPC-A1 cells did not 
significantly alter proliferation compared with the control cells 
(P>0.5 respectively). In conclusion, we have demonstrated 
that BMP7 has an important role in controlling lung cancer 
cell motility and invasiveness, without affecting the growth 
process, cell proliferation and cell apoptosis. A higher BMP7 
expression may be an indicator for bone metastasis. The thera-
peutic role of BMP7 warrants further investigation.
Introduction
Lung cancer is one of the most fatal tumours worldwide. 
Distant metastasis is an important cause for the poor prog-
nosis. Of the factors related to metastasis, bone morphogenetic 
proteins (BMPs) have been recently shown to regulate the 
aggressiveness of cancer cells (1-7). BMPs are multifunctional 
signaling molecules belonging to the transforming growth 
factor-β (TGF-β) superfamily, which play important roles 
in multiple cellular processes such as cell growth, differen-
tiation, migration and apoptosis in various types of cancer 
(8-12). The Smad-dependent signaling pathway has been 
proven to be the canonical pathway for BMP function (13). 
In lung cancer, expression of the BMP family members has 
also been reported (1,14). For example, BMP2 protein could 
stimulate growth, migration and invasion of lung cancer cells, 
and is overexpressed in virtually all types of lung cancers, 
including non-small cell lung cancer (NSCLC) and small cell 
lung cancer (SCLC). Silencing of BMP3b expression during 
NSCLC development has been reported and the BMP3b 
promoter has been found to be methylated. Activation of the 
BMP4 signaling pathway negatively regulates the growth, 
and induces senescence of A549 lung adenocarcinoma cells. 
Thus, there may be a contrasting response to any given BMP, 
depending on the tumour and cell type. Despite the discordant 
results defining the specific effects of BMP7 in various types 
of cancer, published data underscore the important role that 
BMP7 plays in tumour development and metastasis. The 
expression of BMP7 in particular correlates with tumour 
progression and disease recurrence. In mammary epithelial cell 
cancer (4,15-17), BMP7 regulates the proliferation, migration, 
invasion and apoptosis, and has been associated with bone 
metastases, acting as a LIM domain-only 4 (LMO4) responsive 
gene. Furthermore, BMP7 inhibits estradiol-induced prolifera-
tion. In gastric cancer (5), however, the BMP7 promoter has 
been shown to be methylated, suggesting a possible suppres-
sive role in the carcinogenic process. In prostate cancer 
(18-21), BMP7 exposure can modulate biological behaviour 
in a cell type-specific manner. It induces proliferation, inva-
siveness and exerts strong protection against stress-induced 
apoptosis through upregulating survivin activity, and restoring 
the starvation-induced suppression of c-jun NH2 terminal 
kinase (JNK) activity. In contrast, administration of BMP7 has 
been shown to inhibit bone metastases and inhibit epithelial-
mesenchymal transition (EMT).
In our previous research study (5), 6 lung cancer cell lines 
were found to have almost no BMP7 expression, but with 
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differing levels of BMP receptor expression. However, BMP7 
was found to have an important role in controlling lung cancer 
cell motility. The most demonstrable effects of BMP7 on lung 
cancer cells were its inhibitory effects on matrix adhesion, 
motility and in vitro invasiveness by activating an intracellular 
signaling pathway involving alterations in crosstalk between 
SMAD/AR and the Wnt signaling pathways. In the present 
study, we investigated the biological function of BMP7 in lung 
cancer cells and explored the possible link between BMP7 and 
bone metastasis in patients with lung cancer.
Materials and methods
Immunohistochemistry. Seventy-five fixed and paraffin-
embedded primary pulmonary cancer samples were acquired 
from the Department of Pathology, Peking University. Ethic 
approval was given by the local Research Ethics Committee. 
Sections (5 µm) were routinely processed, and stained with 
a mouse monoclonal anti-BMP7 antibody (Santa Cruz 
Biotechnology, Inc., Santa Cruz, CA, USA) at a concentration of 
2 µg/ml, followed by the incubation with HRP-conjugated rabbit 
anti-mouse secondary antibody (Sigma-Aldrich, Poole, Dorset, 
UK). The visualization of antibody staining was developed 
using a DAB HRP Substrate-Chromogen 2 liquid component kit 
with haematoxylin counterstaining. For determination of BMP7 
immunoreactivity, cytosolic staining of yellowish or brownish 
granules was graded as follows: 0, for background staining; 1, 
for negative staining; 2, for moderate staining; and 3, for strong 
staining. In addition, positive staining areas in the entire tissue 
section were graded as follows: 0, for <5%; 1, for 5-25%; 2, for 
26-50%; 3, for 51-75%; and 4, for 76-100%. When combining 
these two parameters, 0-2 and >2 were considered negative or 
moderate and positive staining, respectively (Fig. 1).
Cell culture and supplements. A549 (BMP7-negative) and 
SPC-A1 (BMP7-positive) lung cancer cell lines were main-
tained under standard cell culture conditions in RPMI-1640 
supplemented with 10% fetal bovine serum (FBS) (Sigma-
Aldrich). Tissue culture media and supplements were obtained 
from Invitrogen (Pasley, UK).
Silencing of BMP7 expression by shRNA in SPC-A1 cells 
and BMP7 overexpression in A549 lung cancer cells. A 
recombinant human BMP7 inducible expression system 
(Tet-On system) was purchased from R&D Systems. Sequences 
of BMP7 shRNA (Table I) were inserted into the pGPU6/GFP/
Neo vector. Pulmonary tumour SPC-A1 cells were cultured in 
a cell culture flask containing DMEM (Sigma-Aldrich) supple-
mented with 10% fetal bovine serum and 4 mM L-glutamine. 
Lipofectamine™-mediated transfection was performed 
according to the manufacturer's instructions. Transfection 
efficiency was monitored by the expression of GFP protein. 
The target sequence of BMP7 shRNA is listed in Table I. The 
mRNA and protein levels of BMP7 were measured at 72 h post-
infection.
We constructed a eukaryotic expression system for human 
BMP7. The full length BMP7 gene sequence was amplified 
by reverse transcription-polymerase chain reaction (RT-PCR) 
using the primers listed in Table I. The PCR product was T-A 
cloned into a pEF6/v5-His cloning vector (Invitrogen) which 
has an elongation factor α promoter (EF6) and the blasticidin 
resistance gene (for mammalian cells) and the ampicillin 
resistance gene (for prokaryotic cells). Plasmids were used to 
transfect A549 cell line with Lipofectamine. A549 cells with 
stable BMP7 expression were selected with blasticidin (5 µg/
ml) for up to 2 weeks.
The BMP7 full length gene was inserted into the 
Tet-On system. The BMP7 gene containing vector was 
transfected together with pHelper1.0 and the lentiviral helper 
plasmid pHelpler2.0 to generate the respective lentiviruses 
into 293T cells. Viral particles were collected from the cell 
culture media and used to transduce A549 cells. The mRNA 
and protein levels were measured after the induction with 
different concentrations of doxycycline (DOX).
RT-PCR. Total cellular RNA was extracted using the TRIzol 
reagent following the manufacturer's protocol, and genomic 
DNA was digested by DNase I. cDNAs were synthesized with 
2 µg of total-RNA using the iScript cDNA synthesis kit (Bio-
Rad, Hemel Hempstead, UK). Primers for BMP7 and GAPDH 
are listed in Table I. GAPDH was used as a loading control.
Table I. Primer sequences.
Primer Sequence
shRNA for BMP7 Sense GATCCAAAAAAGGTTTGATCTTTCCAAGATCCTCTCTTGAAGG
  ATCTTGGAAAGATCAAACC
 Antisense CACCGGTTTGATCTTTCCAAGATCCTTCAAGAGAGGATCTTGG
  AAAGATCAAACCTTTTTTG
Full length BMP7 Forward ATGCACGTGCGCTCACTGCGAG
 Reverse CTAGTGGCAGCCACAGGCCCG
BMP7 Forward GAATTCTTCCACCCACGCTACC
 Reverse TGATGTCAAACACCAGCCAGC
GAPDH Forward AGGTCGGAGTCAACGGATTTG
 Reverse GTGATGGCATGGACTGTGGT
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Western blot analysis. Whole cell lysates and cytoplasmic 
proteins were prepared. Proteins were separated on 
SDS-PAGE and transferred to polyvinylidene f luoride 
membranes. Membranes were blocked with 5% nonfat dried 
milk in TBST (15 mM Tris-HCl, pH 7.4, 0.9% NaCl, and 0.05% 
Tween-20, pH 7.4) followed by blot analysis with specified 
antibodies: mouse monoclonal anti-human BMP7 antibody 
(MAB3541, 1:5,000; R&D Systems); and rabbit anti-mouse 
secondary antibody (1:1,000). Immunoreactive bands were 
detected using SuperSignal West Femto Chemiluminescent 
Substrate. Experiments were performed at least twice with 
consistent results.
Cell migration assay. Transwell invasion assays were performed 
following the manufacturer's guidelines. Briefly, 5x104 cells 
in DMEM + 0.1% BSA were plated in 24-well plates with 
DMEM + 5% FBS as a chemoattractant. After 24 h, cells that 
had migrated through and adhered to the other side of the insert 
were fixed and stained with 0.5% (w/v) crystal violet. Invading 
cells on the bottom of the filters were imaged by fluorescence 
microscopy. Five high-power fields were counted per filter to 
score for invasion. The cell number was quantified with the 
ImageJ software.
Wound healing assay. Cells were cultured to confluence in a 
plate before scratching with a 200 µl pipette tip. Debris was 
removed by extensive washing with PBS and the cells were 
further incubated for another 48 h. The closure of the induced 
wound, through the migration of cells, was tracked and 
recorded over a 36-h period at five different locations under 
x20 magnification by a microscope and analyzed using the 
Metamorph version 7.0 software.
Colony formation assay. Cells were seeded into plates at 
a density of 500 cells/plate. Triplicate plates were set up for 
fortnight incubation periods. Following sufficient incubation, 
the plates were fixed in 4% formaldehyde and stained with 
0.5% crystal violet, allowing for the detection of cell density 
by spectrophotomeric analysis of the resulting solutions. 
Absorbance was measured using a Bio-Tek EL9 800 multi-
plate reader (Bio-Tek Instruments, Inc., Winooski, VT, USA).
Cell proliferation assay. Proliferation was determined by the 
MTT assay. Cells (2.5x105) were cultured in 96-well culture 
plates. The cells were resuspended in RPMI-1640 containing 
10% FBS medium, and divided into groups according to the 
study design and were cultured for 0, 24, 48, 72, 96 and 120 h. 
The relative cell counts were determined using the MTT-based 
Cell Growth Determination kit TOX-1 and the BrdU colori-
metric kit, according to the manufacturer's instructions. Each 
experiment was performed in triplicate.
Flow cytometry analysis. To detect intact, necrotic and apop-
totic cells, flow cytometry was performed. A549 and SPC-A1 
cells were incubated for 72 h at 37˚C in 5% CO2. After 24 h 
of incubation, cells were harvested and assayed for apoptosis 
using the Annexin V-FITC apoptosis detection kit, Imgenex, 
according to manufacturer's instruction. Cells were analyzed 
in FACSCalibur Analyzer (Becton-Dickinson) using the 
CellQuest Pro software.
Statistical analysis. Statistical significance was determined 
by the Mann-Whitney test for continuous variables and by 
the χ2 or Fisher's exact test or one-way ANOVA test for cate-
gorical variables. P-values <0.05 were considered statistically 
significant. Statistical tests were performed using the software 
SPSS 18.0 (SPSS Inc., Chicago, IL, USA).
Results
Clinical and prognostic analysis of BMP7 gene expres-
sion in lung cancer. Normal and tumour lung tissues had 
different profiles of BMP7 staining. Strong (Fig. 1A-D), 
weak (Fig. 1G and H) and negative (Fig. 1E and F) stainings 
were seen in human lung tumour tissues. The relationship 
between BMP7 expression and the status of bone metastasis 
was analyzed. All tumours from the five patients who had 
bone metastasis were negative for BMP7 (Table II). This was 
significantly different from tumours from patients who did not 
develop bone metastasis (P=0.040) (Table II), indicating that 
BMP7 may have some role in the bone metastasis process of 
lung cancer cells. We also observed that all 4 small cell lung 
cancer (SCLC) tissue specimens had no BMP7 expression, 
illustrating that BMP7 may have a less important role in SCLC. 
We also compared the expression status of BMP7 according to 
the main tumour types, tumor status, lymph node status and 
vessel status in the cohort. In the cohort of lymph node status, 
N0 tumours had a trend of low positive BMP7 expression, but 
this did not reach statistical significance (P=0.161).
Figure 1. BMP7 staining in human lung cancerous and paracancerous tis-
sues. (A-D) Strong staining of BMP7 protein on pulmonary cancerous tissue 
specimens. (E and F) Negative expression of BMP7 protein on pulmonary 
cancerous tissue specimens and (G and H) moderate expression on para-
cancerous tissue. (Original magnification, x100 and x400).
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BMP7 expression was not correlated with the overall survival 
time in lung cancer patients. The current cohort was moni-
tored during a period of 48 months follow-up. After 48 months 
of follow-up, patients were analysed regarding the survival 
time based on the BMP7 expression level in cancer tissue. 
The mean (SD) survival time was 33.58±2.714 months. 
Cumulative survival curves were calculated using the Kaplan-
Meier method. In patients with a low level of BMP7 expression 
(negative or moderate staining) in cancer tissues, the mean 
survival time was 32.184 (95% CI, 28.6-35.7) months. In 
patients with a high expression level of BMP7 (strong staining) 
in cancer tissues, the mean survival time was 30.1 (95% CI, 
19.2-40.946) months. The expression status of BMP7 was not 
correlated with the overall survival time (P=0.374) (Fig. 2).
Modification of BMP7 expression by shRNA or inducible 
Tet-On system in lung cancer cells. To investigate the biological 
role of BMP7 gene in lung cancer cells, in vitro, we knocked 
down the BMP7 transcript in the human lung cancer cell line 
SPC-A1 by the shRNA constructed Pgpu6/GFP/Neo vector. As 
shown in Fig. 3, we designed four shRNAs targeting sites 1053, 
888, 999 and 1198. RT-PCR and western blot analysis showed 
that shRNA designed for site 999 had the highest knockdown 
efficiency in comparison with the other sequences (Fig. 3B). So 
we chose this shRNA for further investigation. 
In the contrary, overexpression of BMP7 was acquired in 
A549 cells which have low level of endogenous BMP expres-
sion (Fig. 3A). A549 cells were transfected with the BMP7 
inducible expression system (Tet-On system) and success-
fully expressed BMP7 protein with treatment with different 
concentrations of DOX as shown by RT-PCR and western 
blot analysis (Fig. 3C). According to the induction efficiency, 
three DOX concentrations (10, 100 and 1,000 ng/ml) were 
chosen for comparison. A549 cells also successfully expressed 
BMP7 protein when transfected with a BMP7 overexpression 
construct (pEF6/v5-His vector).
Effect of the BMP7 gene on lung cancer invasion ability 
in vitro. Downregulation of BMP7 expression significantly 
Table II. Clinicopathological information of the study cohort.
Clinicopathological feature Cases BMP7 positive cases P-value
Histological type
  Squamous 31   7 0.543
  Adenocarcinoma 36   6
  Small cell lung cancer   4   0
  Other type   4   1
Tumor status
  T1+T2 51   8 0.254
  T3+T4 24   6
Lymph node status
  N0 33   4 0.161
  N1+N2 42 10
Bone metastasis status
  Bone metastasis   5   0 0.040
  No bone metastasis 52 13
  Bone scan abnormity 18   1
Vessel status
  Vessel carcinoma embolus 15   5 0.107
  No vessel carcinoma embolus 60   9
Figure 2. Expression of BMP7 in cancer tissue was not correlated with prog-
nosis. Kaplan-Meier analysis of overall survival of lung cancer patients is not 
correlated with the expression status of BMP7 protein (P>0.05).
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inhibited the invasiveness of SPC-A1 cells (Fig. 4) (P<0.001). 
Overexpression of BMP7 through transfection with a BMP7 
expression plasmid significantly increased the invasiveness of 
A549 cells compared with control-transfected cells (P=0.003). 
Dox (10, 100 and 1000 ng/ml) induced BMP7 expression in a 
dose-dependent manner (Fig. 3Ca). In accordance, the levels 
of BMP7 expression were significantly correlated with the 
invasiveness of the A549 pulmonary cancer cells (P<0.001, 
respectively).
Effect of the BMP7 gene on lung cancer wounding closure 
ability in vitro. To investigate whether the expression of BMP7 
could influence the motility of lung cancer cells, the A549 
cells were transfected with BMP7 expression plasmid, and cell 
motility was monitored by the wound healing assay. Forced-
expression of BMP7 dramatically increased the motility of the 
A549 cell line; and from an early time point of 6 h to the end 
of the experiments, a noticeable difference was seen compared 
with control cells (P<0.001). A statistically significant differ-
ence among BMP7 induced expression A549 cells became 
apparent approximately half way through the experiment at 
the 12-h time point (P<0.001). In contrast, BMP7 downregu-
lation decreased motility of SPC-A1-999 pulmonary tumour 
cells compared to SPC-A1 cells, which indicated migration of 
BMP7-iRNA transfected cells. However, the results were not 
statistical different (P=0.12) (Fig. 5).
Figure 3. Reduced and induced expression and overexpression of BMP7 protein in lung cancer cells. (A) A549 cells transfected with BMP7 plasmid (A549OP 
cells) expressed BMP7 as shown using the RT-PCR method (Aa and b) and western blot analysis (PC, positive control). Expression status of BMP7 transcripts 
in SPC-A1 cells through shRNA-mediated depletion of BMP7 mRNA was strongly decreased for shRNA target 999 when compared with the other targets 
(1053, 888, 1198). (Ba and c) shRNA designed for four different targets could reduce BMP7 expression in SPC-A1 cell using RT-PCR and western blot analysis. 
(Bb and d) Normalised band volumes of BMP7 expression in SPC-A1 cells. (C) Induced expression levels of BMP7 in pulmonary tumour cell lines by RT-PCR 
and western blot analysis using GAPDH expression as the control. Three DOX concentrations were chosen for the induction model (10, 100 and 1,000 ng/ml).
  A   B
  C
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Effect of the BMP7 gene on lung cancer colony forming ability 
in vitro. The in vitro colony forming assay showed a significant 
higher rate of growth in BMP7 forced-expressing pulmonary 
A549 tumour cells, compared with A549wt and A549-nc cells, 
which affected A549 colony formation (P<0.001). BMP7-
induced expression in the A549 cell line resulted in a compared 
gradual increased capacity of this cell line to form colonies 
(P<0.001, respectively). In contrast to overexpression, BMP7 
downregulation of orthotopically implanted SPC-A1-999 cells 
decreased the growth compared with SPC-A1-nc pulmonary 
cancer cells (P=0.001) (Fig. 6).
BMP7 expression does not affect lung cancer growth. Over-
expression of BMP7 in A549 and under-expression in SPC-A1 
cells did not significantly alter proliferation compared with the 
control cells (P>0.5, respectively) (data not shown). Assays 
were then carried out using flow cytometry with Annexin V 
antibodies to assess the apoptotic ratio. Overexpression of 
BMP7 in A549 cells and knocking down of endogenous 
BMP7 in SPC-A1 did not affect the proportion of apoptotic 
cells (P>0.5) (data not shown).
Discussion
BMP7 controls epithelial homeostasis by preserving the 
epithelial phenotype. New evidence suggests the importance 
of BMP7 in the development of an epithelial cancer and in 
metastatic behaviour. Aberrant BMP7 expression during 
tumour progression has been reported in a few cancer types, 
including colorectal cancer, breast cancer, melanoma, and 
prostate cancer (12,15,18,21-26). High levels of BMP7 have 
been detected in bone metastasis of prostate cancer, and 
breast carcinoma as they progress to a more aggressive 
phenotype (3,4,9,15). Upregulation of BMP7 expression in 
metastatic cells has been suggested to be a critical compo-
nent of osteoblastic lesion development. BMP7 has been 
shown to have an influence on proliferation, migration and 
invasion, which in turn has a significant influence on the 
aggressiveness of pulmonary tumour cells (23). For example, 
Notting et al (10) have reported that BMP7 inhibits tumour 
growth of human uveal melanoma. Buijs et al (18) showed that 
loss of BMP7 expression during prostate cancer progression 
could contribute to the acquisition of an invasive phenotype. 
Similar results have been reported in breast cancer cells (17). 
However, exogenous BMP7 increases cell migration and the 
invasion process. We have recently demonstrated there was 
almost no BMP7 expression and different levels of BMP 
receptor expression in lung cancer cell lines (5).
In clinical analysis, we found there were no significant 
relationship between BMP7 expression status in primary 
pulmonary tumour and tumour stage, lymph node status, 
vessel carcinoma embolus status and most interestingly no 
correlation with the survival of the patients. However, we 
found a significant correlation between BMP7 expression in 
cancer and the bone metastasis status (P=0.04). This result 
thus suggest that BMP7 has some role in the process of lung 
Figure 4. Cell invasion assay. The BMP7 gene could significantly increase the number of invasive lung cancer cells overexpressing BMP7 (BMP7-over, 
BMP7-nc), or with induced expression (A549-a, A549-b, A549-c) of BMP. In those with reduced expression of BMP (SPC-A1-999) a decrease in the number 
of invasive pulmonary cancer cells is shown.
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cancer metastasis through the blood vessels, which may reflect 
cancer colony formation ability is important in this process. 
BMP7 protein may also be a useful tool in identifying the bone 
metastasis status.
Tissue invasion and metastasis are hallmarks of malignant 
tumours. Cancer cell metastasis to distant organs is the major 
cause of death in almost all forms of cancer. Metastasis is a 
multi-step process, depends not only on rapid proliferation of 
tumour cells, but also on other biological behaviors including 
motility, invasiveness, and metastatic potential (28,29). 
Tumour invasion is a critical step in tumour metastasis, and the 
understanding of this process may lead to appropriate therapies 
for treating cancer. BMP7 has been shown to be responsible 
for the increase in experimental endothelial cell metastasis 
and is further associated with metastatic disease in pulmonary 
tumour. Furthermore, it has also been shown to enhance cell 
invasion and migration in melanoma, and prostate as well as 
colon cancer cell lines, respectively (3,6,18). The same appears 
to be true for lung cancer cells as shown in the present study, 
in BMP7-transduced pulmonary tumour cells using in vitro 
scratch migration assays. Overexpression of BMP7 increased 
the cellular motility of A549 cells. A significant decrease in 
migrational rates was seen following downregulation of 
BMP7 in SPC-A1 999 cells. Collectively, the present in vitro 
study shows that BMP7 was positively associated with cell 
migration. This study also showed that upregulated expression 
of BMP7 was related to the invasion potentials of A549 cells, 
suggesting a role of BMP7 in lung cancer development and 
progression. In vitro overexpression of BMP7 in A549 cells 
caused increased colony formation, following culture on a 
Matrigel base, in comparison to A549 control cells. In keeping 
with this, a significant reduction in colony formation BMP7-
downregulated and BMP7 induced expression cells were seen. 
Together, these data suggest that BMP7 may positively impact 
human pulmonary tumour growth in vitro, which may bring 
about a promotion in tumour development in vivo.
Figure 5. Wound healing assay. The BMP7 gene significantly increases the healing distance of lung cancer cells compared to control in the BMP7 overexpressing 
(BMP7-over, BMP7-nc), the induced expression (A549-a, A549-b, A549-c) and the reduced expression (SPC-A1-nc, SPC-A1-999) models.
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It has been demonstrated that BMP7 can regulate the 
invasion and motility of lung cancer cells, via activating 
certain intracellular signaling pathways (19,21,22), such as 
the SMAD pathway, without affecting the growth process. 
In keeping with this, data from the MTT cell proliferation 
assay showed no differences in cell viability and proliferation 
between control and A549 cells. BMP7 has been indicated to 
act as a mediator/regulator of cell survival and apoptosis in 
several tumour cell lines (3,6-8,13,25,26,27), including pros-
tate cancer cells, colon cancer cells, breast cancer cells and 
melanoma cells and renal cancer cells. In the present study, 
our results from the apoptosis assay showed that BMP7 offers 
no significant protection against apoptosis in the tumour cells 
transfected with BMP7 in vitro. Meanwhile, downregulation 
of BMP7 detected in SPC-A1 in the study confirmed the role 
for BMP7 in the development of A549 by inhibiting apoptosis, 
indicating that the role of BMP7 in the regulation of apoptosis 
is tumour-type and cell-type dependent.
In conclusion, we have demonstrated that BMP7 has an 
important role in controlling lung cancer cell motility and 
invasiveness, without affecting the growth process, cell prolif-
eration and cell apoptosis in this cell type. A higher BMP7 
expression may be an indicator for bone metastasis. The thera-
peutic role of BMP7 warrants further investigations.
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